Clinical trial
A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of…
NCT00269971 · Janssen-Ortho Inc., Canada, Industry · Withdrawn
Key facts
| NCT number | NCT00269971 |
|---|---|
| Title | A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery. |
| Official title | A Parallel Group Placebo-Controlled Study to Determine an Effective Dose Regimen for EPREX (Epoetin Alfa) Sterile Solution to Reduce Transfusion Requirements in Patients Undergoing Major Elective Orthopedic Surgery |
| Lead sponsor | Janssen-Ortho Inc., Canada, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia, Blood Transfusion, Orthopedic Surgery |
| Intervention type | Drug |
| Interventions | epoetin alfa |
| Enrollment | 0 |
| Start date | May 1, 1996 |
| Completion | Apr 1, 1999 |
| First posted | Dec 26, 2005 |
| Last update posted | Sep 20, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: